Depression 6 - Translational

[P458] Understanding the Impact of CYP2D6-Mediated Venlafaxine Pharmacokinetics on Treatment Outcomes in Late-Life Depression

*Xiaoyu Men^1,2, Zachary L. Taylor^3,4, Victoria S. Marshe⁵, Daniel M. Blumberger^2,6, Jordan F. Karp⁷, James L. Kennedy^2,6, Eric J. Lenze⁸, Charles F. Reynolds III⁹, Cristiana Stefan^2,10, Benoit H. Mulsant^2,6, Laura B. Ramsey^3,4,11, Daniel J. Müller^1,2,6 (1. Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada , 2. Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada, 3. Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA, 4. Division of Clinical Pharmacology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA, 5. Department of Neurology, Columbia University Irving Medical Center, New York, NY, USA, 6. Department of Psychiatry, University of Toronto, Toronto, ON, Canada, 7. Department of Psychiatry, The University of Arizona College of Medicine, Tucson, AZ, USA, 8. Department of Psychiatry, Washington University, St. Louis, MO, USA, 9. Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA, 10. Clinical Laboratory and Diagnostic Services, Centre for Addiction and Mental Health, Toronto, ON, Canada, 11. Division of Research in Patient Services, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA)

Keywords:Pharmacogenetics, Pharmacokinetics, Depression